NEOGEN
ActiveSummary
NEOGEN has been active since 1991 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €11.7m and a net result of €3.0m. Equity is growing by ~9.4% per year across the filed fiscal years. Its solvency ranks better than 82% of 50 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.5% (very low).
Checked score
Score 2024
Axes · tick = 2023
Profitability94▼-2
Solvency100▲+9
Growth85=
Track record100
Bankruptcy probability, 12 months
0.5%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €950,000 at 30 days acceptable
Liquidity ample (current ratio 41.91 against 13.9 in 2023; short-term debt: 2.2% and cash: 0.3% of total assets), and 23.1% of the assets are financed with debt.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
76.9%
Return on assets
19.9%
Age of the figures
21 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 25-09-2025, 56 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
56 d late
2023
22 d early
2022
29 d late
2021
26 d early
2020
40 d late
2019
17 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 10 days after the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
How much credit can you give this customer, and on what term?Credit simulator What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check Which other companies belong to the same group?A.forall Group · 9 companies How does this company compare with its sector?Sector benchmark
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, abbreviated schema
In the rankings
#5 company by equity in the Brussels-Capital Region, Pharmaceuticals sector#8 company by total assets in the Brussels-Capital Region, Pharmaceuticals sector#9 oldest company in the Brussels-Capital Region, Pharmaceuticals sector
Turnover
€2.4m▲ 61.3%
2018 · €1.5m
EBIT margin
-101.9%▼ 117.7pp
2018 · 15.8%
Net result
€3.0m▲ 5.9%
2023 · €2.9m
Working capital
€13.6m▲ 27.2%
2023 · €10.7m
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20202021202220232024
Turnover€2.4m
Operating result-€2.5m▼ 313%€30,702€744,065▲ 2,324%€2.4m▲ 217%€2.4m▲ 0.7%
Net result-€2.0m▼ 255%€76,058€939,744▲ 1,136%€2.9m▲ 203%€3.0m▲ 5.9%
EBIT margin-101.9%
Equity€4.8m▼ 23.2%€4.9m▲ 1.6%€5.8m▲ 19.3%€8.7m▲ 49.0%€11.7m▲ 34.8%
Total assets€6.7m▼ 13.8%€11.0m▲ 64.4%€11.1m▲ 0.8%€13.1m▲ 18.0%€15.2m▲ 16.0%
Debt€1.9m▲ 25.0%€6.1m▲ 223%€5.3m▼ 13.8%€4.4m▼ 16.1%€3.5m▼ 20.9%
Working capital€1.5m▲ 1.1%€6.8m▲ 350%€8.0m▲ 18.5%€10.7m▲ 33.0%€13.6m▲ 27.2%
Staff (FTE)
Result per fiscal year
Operating resultNet result
The operating result has risen four years in a row; 2024 is 1% above 2023 and is the highest result in the available series.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €15.2m
Fixed assets
€1.3m ▼ 19.3%
Current assets
€13.9m ▲ 21.0%
Equity and liabilities €15.2m
Equity
€11.7m ▲ 34.8%
Debt
€3.5m ▼ 20.9%
Debt's share of the balance-sheet total falls from 33.9% to 23.1%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€2.7m▼
2023 · €2.8m
Cash flow
€3.4m▲
2023 · €3.3m
Current ratio
41.91▲
2023 · 13.90
Debt to equity
0.30▼
2023 · 0.51
ROE
25.8%▼
2023 · 32.9%
ROA
19.9%▼
2023 · 21.8%
Interest coverage
116.27▼
2023 · 700.28
Debt ≤ 1 year
€331,329▼
2023 · €825,691
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 1,552 companies that looked in July 2024 the way this one looks now, 0.1% went bankrupt within 24 months and 97% are still going.
- Medium-sized
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.1%
went bankrupt
3.2%
stopped otherwise
97%
still going
For this company itself Checked computes a bankruptcy probability of 0.5% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.6% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 1,552 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Turnover70 | €2.4m | - | - | - | - | - |
| Non-recurring operating income76A | €43,446 | - | - | - | €65,262 | - |
| Goods, raw materials, services and sundry goods60/61 | €1.8m | - | - | - | - | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €1.3m | €746,971 | €1.0m | €437,411 | €372,143 | ▼ 14.9% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | -€248,641 | €2,979 | €37,589 | -€44,341 | €1,860 | ▲ 104% |
| Other operating charges640/8 | €305,701 | €1,848 | €868 | €960 | €32,153 | ▲ 3,248% |
| Non-recurring operating charges66A | €2.5m | €824,835 | €2,450 | €46,674 | - | - |
| Gross operating margin9900 | €1.4m | €1.6m | €1.8m | €2.8m | €2.8m | ▼ 0.7% |
| Operating profit (loss)9901 | -€2.5m | €30,702 | €744,065 | €2.4m | €2.4m | ▲ 0.7% |
| Financial income75/76B | €323,438 | €57,790 | €197,856 | €497,268 | €668,502 | ▲ 34.4% |
| Recurring financial income75 | €323,438 | €57,790 | €197,856 | €497,268 | €668,502 | ▲ 34.4% |
| Financial charges65/66B | €158,891 | €12,434 | €2,177 | €3,992 | €23,615 | ▲ 492% |
| Recurring financial charges65 | €158,891 | €12,434 | €2,177 | €3,992 | €23,615 | ▲ 492% |
| Profit (loss) for the period before taxes9903 | -€2.3m | €76,058 | €939,744 | €2.9m | €3.0m | ▲ 5.9% |
| Income taxes67/77 | -€298,300 | - | - | - | - | - |
| Profit (loss) for the period9904 | -€2.0m | €76,058 | €939,744 | €2.9m | €3.0m | ▲ 5.9% |
| Profit (loss) for the period to be appropriated9905 | -€2.0m | €76,058 | €939,744 | €2.9m | €3.0m | ▲ 5.9% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €6.7m | €11.0m | €11.1m | €13.1m | €15.2m | ▲ 16.0% |
| Fixed assets21/28 | €3.3m | €2.8m | €2.0m | €1.6m | €1.3m | ▼ 19.3% |
| Intangible fixed assets21 | €3.3m | €2.8m | €2.0m | €1.6m | €1.3m | ▼ 19.3% |
| Tangible fixed assets22/27 | €8,201 | €7,948 | €6,537 | €5,287 | €4,110 | ▼ 22.3% |
| Plant, machinery and equipment23 | €8,201 | €7,948 | €6,537 | €5,287 | €4,110 | ▼ 22.3% |
| Financial fixed assets28 | €4,694 | €4,694 | €4,694 | - | - | - |
| Current assets29/58 | €3.4m | €8.2m | €9.1m | €11.5m | €13.9m | ▲ 21.0% |
| Amounts receivable within one year40/41 | €3.2m | €8.1m | €9.0m | €11.4m | €13.8m | ▲ 21.2% |
| Trade receivables40 | €2.6m | €1.1m | €793,673 | €1.1m | €754,833 | ▼ 30.2% |
| Other amounts receivable41 | €599,624 | €7.0m | €8.2m | €10.3m | €13.1m | ▲ 26.6% |
| Cash at bank and in hand54/58 | €86,893 | €56,814 | €103,875 | €64,484 | €48,607 | ▼ 24.6% |
| Deferred charges and accrued income490/1 | €97,902 | - | - | - | - | - |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €6.7m | €11.0m | €11.1m | €13.1m | €15.2m | ▲ 16.0% |
| Equity10/15 | €4.8m | €4.9m | €5.8m | €8.7m | €11.7m | ▲ 34.8% |
| Contributions10/11 | €12.4m | €12.4m | €12.4m | €12.4m | €12.4m | = |
| Capital10 | €7.3m | €7.3m | €7.3m | €7.3m | €7.3m | = |
| Issued capital100 | €7.3m | €7.3m | €7.3m | €7.3m | €7.3m | = |
| Outside capital11 | €5.1m | €5.1m | €5.1m | €5.1m | €5.1m | = |
| Share premium1100/10 | €5.1m | €5.1m | €5.1m | €5.1m | €5.1m | = |
| Reserves13 | €209,200 | €213,003 | €259,990 | €402,606 | €553,529 | ▲ 37.5% |
| Non-distributable reserves130/1 | €209,200 | €213,003 | €259,990 | €402,606 | €553,529 | ▲ 37.5% |
| Legal reserve130 | €209,200 | €213,003 | €259,990 | €402,606 | €553,529 | ▲ 37.5% |
| Profit (loss) carried forward14 | -€7.8m | -€7.7m | -€6.8m | -€4.1m | -€1.3m | ▲ 69.4% |
| Amounts payable17/49 | €1.9m | €6.1m | €5.3m | €4.4m | €3.5m | ▼ 20.9% |
| Amounts payable within one year42/48 | €1.9m | €1.4m | €1.1m | €825,691 | €331,329 | ▼ 59.9% |
| Trade debts44 | €1.3m | €1.4m | €1.1m | €825,691 | €331,329 | ▼ 59.9% |
| Suppliers440/4 | €1.3m | €1.4m | €1.1m | €825,691 | €331,329 | ▼ 59.9% |
| Taxes, remuneration and social security45 | €5,454 | - | - | - | - | - |
| Taxes450/3 | €5,454 | - | - | - | - | - |
| Other amounts payable47/48 | €550,689 | - | - | - | - | - |
| Accrued charges and deferred income492/3 | €31,516 | €4.7m | €4.2m | €3.6m | €3.2m | ▼ 11.9% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€2.0m | €76,058 | €939,744 | €2.9m | €3.0m | ▲ 5.9% |
| + Depreciation and write-downs630 | €1.3m | €746,971 | €1.0m | €437,411 | €372,143 | ▼ 14.9% |
| Operating cash flow (approximation) | -€699,250 | €823,029 | €2.0m | €3.3m | €3.4m | ▲ 3.1% |
| Investment in fixed assets (approximation) | - | -€258,847 | -€149,515 | -€88,067 | -€58,648 | ▲ 33.4% |
| Change in cash | - | -€30,079 | €47,061 | -€39,391 | -€15,877 | ▲ 59.7% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
25-09
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 56 days late
2024
31-12
Financial
Highest result since 2018net €3.0m ▲5.9%
Operating result €2.4m, net result €3.0m, both a record.
31-12
Financial
Liquidity triplescurrent ratio 41.91
Current ratio from 13.90 to 41.91; short-term debt falls from €825,691 to €331,329.
31-12
Financial
Equity above €10mEq €11.7m ▲34.8%
4 profitable years in a row build equity to €11.7m.
09-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
29-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 29 days late
2022
31-12
Financial
Equity above €5mEq €5.8m ▲19.3%
2 profitable years in a row build equity to €5.8m.
05-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Back to profitnet €76,058
Net result €76,058 after 2 loss-making years.
31-12
Financial
Liquidity triplescurrent ratio 5.78
Current ratio from 1.80 to 5.78; short-term debt falls from €1.9m to €1.4m.
09-09
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 40 days late
2020
31-12
Financial
Weakest financial yearnet -€2.0m
Net result drops to -€2.0m, the lowest in the series; recovery starts the following year.
Show earlier events
14-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
09-07
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
26-10
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2017
08-11
NBB filing
Annual accounts filed
fiscal year 2017 · full schema · 8 days late
2016
26-10
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 20 acts read
About the unread acts
We know of 20 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
20 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Anderlecht · 1 establishment unit since 1992
Ground area
5,534 m²
Building footprint
1,445 m²
Volume, LiDAR
24,182 m³
Parcel 21307F0088/00F000, Brussels · tallest building 21.7 m, ±6 floors. Linked by address, not a title deed.
10
companies at this address
See who is registered here
1 establishment unit
Marie Curiesquare 50, 1070 Anderlecht
since 19922.055.632.314
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21307F0088/00F000 | Brussels | 5,534 m² | 1 · 1,445 m² | 21.7 m · 6 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Part of the group
A.forall Group
9 companies
Group, risk and exposure
Owners and holdings
1 ownerChain of control
Highest known parent: A.forall Group. The sources do not say who stands above it.
Owners 1
-
100%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Recognitions · licences · registrations
Legal Entity Identifier
254900BAXEZAE0CAIP09
Similar companies · same sector, comparable size
Upjohn
BE 0552.558.025
Hoeilaart · Eq €12.1m
TILMAN
BE 0458.493.759
Somme-Leuze · Eq €12.8m
Sanico
BE 0404.190.288
Turnhout · Eq €13.3m
CENEXI - LABORATOIRES THISSEN
BE 0843.115.684
Braine-l'Alleud · Eq €13.9m
SMI
BE 0432.408.182
Sankt Vith · Eq €14.0m
Of 148 companies in sector 21201 we hold annual accounts for 116. 60 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded09-12-1991
Fiscal year end31-12
Activities, NACEBEL 2025
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
E-invoicing
Reachable via Peppol
Peppol ID
0208:0445922856
Also
9925:BE0445922856
Registered
29-12-2025
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.